Breast Cancer Clinical Trial
Evaluating the Performance of AI in Evaluating Breast MRI Performed With Dose Reduction
Summary
The purpose of this study is to evaluate the ability of AI to correctly aid in characterization of benign and malignant lesions even when a low dose of gadolinium is administered. This study is relevant for several reasons, most notably being the reduction of MRI dose and decreased gadolinium deposition in the brain. In addition, use of AI may provide increased sensitivity and specificity for the radiologist evaluating a breast MRI exam. Half of the population will have benign pathologies and the other half will have malignant pathologies.
Full Description
The study involves each patient presenting for an initial MRI with a regular dose of gadolinium and then presenting at least 48 hours after (no less than 14 days later) for a ¼ dose (see below regarding dosing) gadolinium MRI exam. Both exams will be performed on a 1.5 Tesla magnet. Both exams will include a full protocol. The full dose contrast exam will be read as standard protocol. All images will be anonymized. Images from the reduced dose study will be collected and an AI algorithm applied. All three anonymized data sets (regular dose, low dose, and AI algorithm applied to low dose) will be provided to the readers.
Readers will be three attending radiologists specializing in breast imaging. Exams will be scored on quality, background parenchymal enhancement (BPE), and lesion conspicuity. Enhancing lesions will be identified and characterized by the radiologists in a document provided.
Eligibility Criteria
Inclusion Criteria for Breast Cancer Patients:
Female patient between ≥ 18 years old and ≤ 99 years old
Patients with newly diagnosed primary breast cancer
Patient able and willing to participate in the trial
Inclusion criteria for Non-malignant indications:
Female patients between ≥ 18 years old and ≤ 99 years old
Be referred for MRI for non-malignant indications (screening or BIRADS 3)
Patients have had prior exam with known enhancing mass, nonmass enhancement, or focus/foci.
Exclusion Criteria:
Non-female patients
Patients < 18 years old
Women who are lactating or pregnant
Patients with recurrent breast cancer
Patients who have already received neoadjuvant chemotherapy
Unable to lie still on the imaging table for one (1) hour
Patients that are unable to undergo MRI evaluation for reasons specific to MRI
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Birmingham Alabama, 35249, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.